|
|
Article: Atrix licenses prostate cancer products in Korea.(Atrix Laboratories, Inc. signs licensing agreement with Han All Pharmaceutical Co., Ltd.)(Brief Article)
- Article from:
- BIOTECH Patent News
- Article date:
- February 1, 2004
CopyrightCOPYRIGHT 2004 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Atrix Laboratories, Inc. (Fort Collins, CO) signed an exclusive licensing agreement with Han All Pharmaceutical Co., Ltd., to develop and commercialize Eligard (leuprolide acetate for injectable suspension) in Korea. Leutenizing hormone releasing hormone (LHRH) agonists, like Eligard, are commonly used for the treatment of hormone-responsive prostate cancer and other indications such as breast cancer and endometriosis around the world.
"Korea is the second largest LHRH market in pan-Asia after Japan and among the top twenty globally," said David R. Bethune, Atrix's chairman and chief executive officer.
Han All Pharmaceutical is a well-established Korean ...
Related newspaper, magazine, and journal articles:
|
|
Article: /C O R R E C T I O N -- Atrix Laboratories, Inc./.
PR Newswire;
March 24, 2003 ;
700+ words
... ... In the news release, Atrix Laboratories to Present at the Banc Of ... issued Friday, March 21, by Atrix Laboratories, Inc. over PR Newswire ... corrected release follows: Atrix Laboratories to Present at the Banc Of ...
|
|